HOMEPRODUCTSSERVICESCOMPANYCONTACTFAQResearchDictionaryPharmaMobileSign Up FREE or Login

PRO 160-120

a combination of Sabal and Urtica extracts
Also Known As:
PRO-160-120; PRO160-120
Networked: 6 relevant articles (0 outcomes, 3 trials/studies)

Bio-Agent Context: Research Results

Experts

1. Schläfke, Sandra: 3 articles (10/2014 - 01/2006)
2. Engelmann, Udo: 2 articles (01/2007 - 01/2006)
3. Funk, Petra: 2 articles (01/2007 - 01/2006)
4. Walther, C: 2 articles (10/2005 - 06/2005)
5. Berges, Richard: 1 article (10/2014)
6. Burkart, Martin: 1 article (10/2014)
7. Oelke, Matthias: 1 article (10/2014)
8. Lopatkin, Nikolai: 1 article (01/2007)
9. Sivkov, Andrey: 1 article (01/2007)
10. Medvedev, Alexander: 1 article (01/2007)

Related Diseases

1. Prostatic Hyperplasia (Benign Prostatic Hyperplasia)
03/01/2006 - "A multicenter, prospective clinical trial was performed to study efficacy and tolerance of a compound drug PRO 160/120 in the elderly men with lower urinary tract symptoms (LUTS) due to benign prostatic hyperplasia (BPH). "
10/06/2005 - "This re-evaluation of a double-blind placebo-controlled therapeutic study of the combined sabal-urtica preparation PRO 160/120 investigates the changes in the irritative symptoms of benign prostatic hyperplasia (BPH) under the test substance in comparison with placebo. "
01/01/2007 - "In an open-label extension of a randomized, double-blind clinical trial, the long-term efficacy and tolerability of a fixed combination of 160 mg Sabal fruit extract WS 1473 and 120 mg Urtica root extract WS 1031 per capsule (PRO 160/120) were investigated in elderly men with moderate or severe lower urinary tract symptoms (LUTS) caused by benign prostatic hyperplasia (BPH). "
06/01/2005 - "The efficacy and tolerability of a fixed combination of 160 mg sabal fruit extract WS 1473 and 120 mg urtica root extract WS 1031 per capsule (PRO 160/120) was investigated in elderly, male patients suffering from lower urinary tract symptoms (LUTS) caused by benign prostatic hyperplasia in a prospective multicenter trial. "
01/01/2006 - "The aim of this prospective, randomized, double-blind, double-dummy, multicenter clinical trial was to investigate the efficacy and safety of PRO 160/120 (Prostagutt forte), a fixed combination preparation of 160 mg Sabal fruit extract WS 1473 and 120 mg Urtica root extract WS 1031 per capsule, in comparison to the alpha1-adrenoceptor antagonist tamsulosin (CAS 106463-17-6) in lower urinary tract symptoms (LUTS) caused by benign prostatic hyperplasia (BPH). "
2. Nocturia

Related Drugs and Biologics

1. tamsulosin (Flomax)